What does the CDSCO (India) Teriparatide package insert say about the 24-month limit?
CDSCO-approved package information for teriparatide in India includes a recommended maximum duration of therapy of 24 months over a patient’s lifetime. This “lifetime” cap is intended to limit exposure to teriparatide.
Why is teriparatide restricted to a maximum of 24 months?
The 24-month limit is based on regulatory safety guidance for teriparatide use and is reflected in the Indian prescribing information. The restriction is designed to reduce long-term risk associated with prolonged use.
How is the 24-month rule counted for patients?
The package insert guidance is that the total time on teriparatide should not exceed 24 months in a lifetime, regardless of whether treatment is continuous or restarted after breaks.
Can patients repeat teriparatide after stopping at 24 months?
No. If the patient has received the maximum recommended lifetime duration (24 months), teriparatide should not be restarted, because the lifetime exposure limit is reached.
What should patients do after completing 24 months?
After completing the teriparatide course, clinicians typically switch patients to an anti-osteoporosis therapy to maintain gains in bone mineral density, consistent with standard osteoporosis management approaches.
Where can I find the exact CDSCO text for the “24 months” statement?
To quote the precise wording from the India teriparatide package insert, you’ll need the specific brand/manufacturer document (package insert PDF or label), because wording can vary slightly by product while keeping the same regulatory limit of 24 months.
If you share the teriparatide brand name (or the manufacturer) you’re using in India, I can help pinpoint the exact section wording about “24 months” and what it says about repeat courses and total lifetime duration.
Sources
No CDSCO package insert document was provided in the prompt, so I can’t cite or quote the exact India insert text here.